Open access
Main clinical, laboratory, and imaging findings of some selected emerging viral infections by organs and systems.
1. Introduction
In recent decades, viral outbreaks have emerged as the most formidable challenges to global health, security, and socioeconomic stability. From the HIV/AIDS pandemic to the catastrophic impact of Ebola in West Africa [1, 2, 3, 4, 5, 6, 7, 8, 9, 10], Zika in the Americas [11, 12, 13, 14, 15, 16, 17, 18, 19, 20], and most recently, the global crisis caused by SARS-CoV-2 [21, 22, 23, 24, 25, 26, 27, 28, 29, 30], the frequency and scale of viral epidemics and pandemics have intensified [31, 32, 33, 34]. This trend reflects a convergence of factors—ecological disruption, globalization, urbanization, climate change, and increased human-animal interface—that have accelerated the emergence and re-emergence of viral pathogens [35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46].
The interconnectedness of today’s world means that localized outbreaks can rapidly evolve into global threats. The COVID-19 pandemic starkly illustrated how quickly a novel virus can cross borders, overwhelm healthcare systems, and disrupt economies and societies at every level [26, 47, 48, 49, 50, 51, 52, 53, 54, 55]. It also highlighted critical weaknesses in preparedness, surveillance, global coordination, and the deep inequities in access to healthcare and vaccines. These lessons remain urgently relevant as new outbreaks continue to emerge, including those caused by known threats like influenza [56, 57, 58, 59, 60, 61, 62, 63, 64, 65] and monkeypox [66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77], and potential threats such as novel coronaviruses and arboviruses [32, 33, 78, 79, 80, 81, 82, 83].
Viral outbreaks do not occur in a vacuum. They intersect with political, social, environmental, and economic dynamics influencing their spread and our responses. Misinformation, vaccine hesitancy, and inadequate health infrastructure can exacerbate outbreaks, while geopolitical tensions may hinder effective global collaboration. Understanding the complexity of these challenges requires a multidisciplinary and One Health approach, recognizing the interconnectedness of human, animal, and environmental health [84, 85].
This book,
This volume aims to inform, challenge, and inspire collective action toward a more resilient and equitable global health future by comprehensively examining past and ongoing outbreaks, emerging pathogens, and strategic responses [86, 87, 88].
Advertisement
2. Epidemiology of viral outbreaks
The epidemiology of viral outbreaks encompasses the study of the distribution, determinants, and dynamics of viral diseases within populations. Understanding these epidemiological patterns is crucial for identifying at-risk populations, implementing effective control measures, and preventing future outbreaks. Viral epidemics and pandemics often exhibit complex transmission dynamics that depend on pathogen characteristics, host factors, environmental influences, and social determinants of health [89, 90].
Viral pathogens can be transmitted through a variety of routes, including respiratory droplets (e.g., influenza, SARS-CoV-2), fecal-oral spread (e.g., hepatitis A, norovirus), vector-borne transmission (e.g., dengue, Zika, chikungunya), and direct contact with infected bodily fluids (e.g., Ebola, HIV) [91, 92, 93, 94, 95, 96, 97, 98, 99, 100]. The reproductive number (R₀), incubation period, and duration of infectiousness are key epidemiological parameters that inform the potential for spread and the design of public health interventions [101, 102, 103, 104].
Globalization and rapid urbanization have amplified the potential for viruses to spread across continents within days. Air travel, trade, and population displacement due to conflict or climate change have created conditions favorable to the rapid dissemination of infectious agents. Additionally, ecological changes such as deforestation and encroachment into wildlife habitats have increased the risk of zoonotic spillover events, where viruses cross species barriers to infect humans, as seen with the Nipah virus [105, 106, 107, 108, 109, 110, 111, 112, 113, 114], SARS, MERS, and SARS-CoV-2 [115, 116].
Modern molecular epidemiology and genomic surveillance have revolutionized the investigation of outbreaks. Whole-genome sequencing enables the real-time tracking of viral evolution, allowing for the identification of new variants and transmission chains with unprecedented speed and accuracy. During the COVID-19 pandemic, genomic data played a crucial role in monitoring the emergence of variants of concern, informing vaccine updates, and shaping public health policy. However, disparities in sequencing capacity between high-income and low- and middle-income countries remain a significant challenge [117, 118].
The burden of viral outbreaks is often unevenly distributed, with marginalized communities experiencing higher morbidity and mortality due to limited access to healthcare, poor living conditions, and systemic inequities. Epidemiological analyses must therefore incorporate a socioecological perspective, recognizing how structural determinants influence vulnerability and resilience [119].
Effective epidemiological surveillance systems, both passive and active, are essential for detecting and responding to outbreaks. Integrating human and animal health surveillance through a One Health framework enhances early warning capabilities and facilitates coordinated action [120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131]. As viral threats evolve, so too must our epidemiological tools and approaches, ensuring they are agile, inclusive, and globally coordinated [132].
Advertisement
3. Main clinical impact of emerging viral diseases
Emerging viral diseases pose significant and multifaceted clinical challenges (Table 1). As new or previously controlled viruses reappear in human populations, they frequently present with variable clinical manifestations, ranging from asymptomatic infection to severe, life-threatening illness. Viral virulence, host immunity, comorbidities, age, and access to healthcare influence the clinical spectrum. These infections strain clinical services and often reveal systemic gaps in healthcare preparedness and response [133, 134].
| System | COVID-19 (SARS-CoV-2) | Ebola virus disease (EVD) | Zika virus | Dengue virus | Chikungunya virus |
|---|---|---|---|---|---|
| General | Fever, fatigue, malaise | Sudden high fever, fatigue | Mild fever, rash | High fever, headache, retro-orbital pain | High fever, rash, fatigue |
| Respiratory | Cough, dyspnea, hypoxia; ARDS in severe cases | Cough is rare, secondary to systemic involvement | Mild or absent respiratory symptoms | Generally absent | Mild cough occasionally |
| Cardiovascular | Tachycardia, myocarditis, thromboembolism | Hypotension, shock in late stages | Rare fetal bradycardia | Hypotension, plasma leakage (severe dengue) | Rare arrhythmias, possible myocarditis |
| Neurological | Headache, anosmia, encephalopathy, stroke | Confusion, delirium in severe stages | Guillain-Barré syndrome, microcephaly and congenital Zika syndrome (fetus) | Encephalopathy, seizures (rare) | Polyarthritis, neuroinflammation (rare) |
| Gastrointestinal | Diarrhea, nausea, vomiting | Profuse vomiting, diarrhea, and abdominal pain | Nausea and vomiting occasionally | Nausea, vomiting, abdominal pain | Nausea, vomiting, mild diarrhea |
| Musculoskeletal | Myalgia, fatigue | Severe myalgia, weakness | Arthralgia (mild) | Myalgia, arthralgia | Severe arthralgia, chronic arthritis-like symptoms |
| Dermatologic | Rash (infrequent), chilblain-like lesions | Petechiae, bleeding, rash in late stages | Maculopapular rash, conjunctivitis | Maculopapular rash, bleeding in severe forms | Maculopapular rash, facial flushing |
| Hematologic | Lymphopenia, elevated D-dimer, and thrombocytopenia | Leukopenia, thrombocytopenia, elevated liver enzymes | Mild leukopenia | Leukopenia, thrombocytopenia, hemoconcentration | Mild thrombocytopenia, lymphopenia |
| Imaging | Chest CT: ground-glass opacities, consolidation | Nonspecific; GI imaging may show fluid accumulation | Neuroimaging: calcifications (congenital cases) | Chest X-ray: pleural effusion (severe cases) | Joint imaging: synovitis, tenosynovitis (rare) |
Table 1.
Respiratory viruses, such as novel influenza strains, SARS-CoV-1, MERS-CoV, and SARS-CoV-2, commonly cause acute respiratory syndromes of varying severity. These can lead to pneumonia, acute respiratory distress syndrome (ARDS), and multiorgan failure. COVID-19, in particular, underscored the diverse clinical impact of respiratory viruses, ranging from mild symptoms to severe complications including thrombosis, cardiac injury, neurological sequelae, and prolonged post-viral syndromes (e.g., Long COVID) [135, 136, 137, 138]. The burden on intensive care units and the need for ventilatory support further complicated the clinical response during pandemic peaks [139, 140].
Hemorrhagic fevers, such as those caused by Ebola, Marburg, Lassa, and Crimean-Congo hemorrhagic fever viruses, are often associated with high case fatality rates. These diseases are characterized by fever, vascular leakage, coagulopathy, and multi-organ dysfunction. Managing these infections requires level isolation and supportive care, which are often unavailable in resource-limited settings where such viruses are endemic or emerging. Clinical outcomes are frequently poor without early intervention, underscoring the importance of rapid diagnosis and supportive therapy [141, 142].
Arboviral infections—including dengue, chikungunya, Zika, and yellow fever—demonstrate the broad clinical impact of emerging viruses. Dengue can cause a range of outcomes, from a mild febrile illness to severe dengue hemorrhagic fever and shock syndrome. Zika virus, though often mild in adults, has devastating effects on fetal development, causing congenital Zika syndrome with microcephaly and other neurodevelopmental anomalies. Chikungunya is primarily associated with febrile polyarthritis, which can persist chronically and impair quality of life [42, 44, 46, 89, 143].
Neurotropic viruses, such as West Nile [144, 145, 146, 147, 148, 149, 150, 151, 152, 153], Japanese encephalitis, and rabies [154, 155, 156, 157, 158, 159, 160, 161, 162] can cause central nervous system involvement, including encephalitis, meningitis, or paralytic syndromes. These diseases often result in long-term neurological impairment or death, particularly in vulnerable populations such as the elderly, immunocompromised, and unvaccinated individuals [163].
Beyond the acute illness, emerging viral diseases often leave a lasting clinical and societal impact. Post-infectious sequelae—neurological, cardiovascular, renal, and psychiatric—are increasingly recognized. In outbreaks, healthcare systems face the challenge of managing acutely ill patients while also addressing their long-term follow-up and rehabilitation needs. The psychological impact on both patients and healthcare workers, including post-traumatic stress and burnout, is substantial and often underestimated [164, 165, 166, 167].
Moreover, co-infections with endemic pathogens (e.g., malaria, HIV, tuberculosis) can alter clinical outcomes, complicating diagnosis and treatment. For example, co-infection with HIV and viral hepatitis or SARS-CoV-2 may exacerbate disease severity and alter therapeutic responses. Immunocompromised individuals are particularly susceptible to prolonged viral shedding, atypical presentations, and poor prognosis [168, 169].
The lack of specific antiviral therapies for many pathogens further challenges the clinical management of emerging viral diseases. In most cases, treatment is supportive, relying on fluid management, respiratory support, and symptomatic care. While vaccines offer a powerful tool for prevention, access and acceptance remain uneven globally. The rapid development of vaccines against COVID-19 has demonstrated the potential of modern biotechnology, however, other emerging threats lack effective preventive or therapeutic options [170].
In sum, the clinical impact of emerging viral diseases is broad and profound. These infections not only cause direct morbidity and mortality but also strain healthcare systems, exacerbate inequities, and create long-term public health burdens. A comprehensive clinical response requires preparedness, training, resource allocation, and investment in research to understand pathogenesis better, develop targeted therapies, and build resilient health systems [171].
Advertisement
4. Research challenges on viral outbreaks
The research landscape surrounding viral outbreaks is complex, rapidly evolving, and challenging to navigate. As emerging and re-emerging viruses continue to pose global threats, timely and robust research is crucial for informing public health responses, therapeutic development, and vaccine strategies. However, logistical, ethical, political, and infrastructural obstacles often hinder conducting high-quality research during outbreaks [81, 82, 83, 89, 90, 135].
One major challenge is the unpredictability of outbreaks, which makes it difficult to establish pre-approved research protocols and mobilize resources swiftly. By the time research frameworks are deployed, the outbreak may already be in decline, leading to missed opportunities for data collection. This was evident in multiple Ebola outbreaks, where delays in initiating clinical trials limited the ability to assess promising therapeutics in real time [87, 88, 102, 170].
Another barrier is limited infrastructure in affected regions, particularly in low- and middle-income countries where many outbreaks originate. Weak laboratory capacity, lack of trained personnel, and insufficient funding impede rapid diagnostics, genomic surveillance, and clinical research. These gaps contribute to delayed pathogen identification, poor case characterization, and limited data sharing [37, 79, 90, 137].
Ethical considerations also present significant challenges. In the urgency of an outbreak, conducting randomized controlled trials while ensuring informed consent, equitable access, and protection of vulnerable populations requires careful planning and robust oversight. Balancing scientific rigor with the humanitarian imperative to offer potentially life-saving interventions remains a delicate endeavor [103, 135, 164, 170, 172].
Data sharing and coordination are often fragmented across national and institutional lines. Proprietary restrictions, a lack of open-access platforms, and geopolitical tensions can delay the dissemination of critical epidemiological and genomic data. The COVID-19 pandemic underscored both the benefits of open science and the consequences of data silos [44, 102, 115, 139, 169].
Finally, funding sustainability for outbreak-related research is typically reactive and short term. Investment tends to surge during crises and decline afterward, undermining long-term preparedness and innovation [173].
To overcome these challenges, the global research community must prioritize collaborative networks, equitable funding mechanisms, adaptable ethical frameworks, and the development of agile research infrastructure. Strengthening these areas is crucial to generating timely, actionable evidence and ensuring a coordinated response to current and future viral threats.
Advertisement
5. Conclusions
Viral outbreaks have become an enduring global threat, testing the resilience of health systems, scientific infrastructure, and international cooperation. From COVID-19 to Ebola, Zika, dengue, and chikungunya, the emergence and re-emergence of viral pathogens continue to reveal critical vulnerabilities in surveillance, clinical response, and research readiness. As outlined in this chapter, the global challenges posed by these outbreaks are multidimensional, spanning epidemiological complexity, clinical burden, research constraints, and the need for coordinated global action.
Epidemiologically, emerging viruses exploit a convergence of risk factors including ecological disruption, urbanization, globalization, and increased human-animal interactions. Rapid spread across borders—often facilitated by asymptomatic carriers and inadequate surveillance—demands vigilant monitoring systems and international data sharing. A One Health approach, integrating human, animal, and environmental health, is fundamental to anticipating and mitigating the next outbreak.
Clinically, these viral diseases exhibit diverse manifestations, affecting multiple organ systems and resulting in acute and long-term health consequences. The differential severity across populations underscores the influence of social determinants, comorbidities, and health inequities. The lack of specific treatments for many emerging viral diseases means that supportive care, early diagnosis, and prevention remain the cornerstones of effective management.
Research during outbreaks, though indispensable, faces significant obstacles. These include unpredictable timing, ethical complexities, logistical constraints, and inequities in funding and infrastructure. The experience of COVID-19 illustrated the critical value of agile research frameworks, open science, and public-private partnerships—but also highlighted enduring disparities between nations in terms of capacity and access.
The global community must shift from reactive crisis management to proactive preparedness. This includes investing in surveillance and laboratory networks, strengthening healthcare delivery systems, fostering transdisciplinary research, and ensuring equitable access to diagnostics, therapeutics, and vaccines. Resilience requires scientific innovation, trust, transparency, and solidarity across borders.
This introductory chapter sets the stage for a deeper exploration of the topics in viral outbreaks addressed in the rest of this book. We aim to contribute to a more coordinated, evidence-based, and equitable global strategy to confront current and future viral threats by advancing our understanding of the underlying challenges and responses.
Advertisement
Acknowledgments
The author acknowledges the use of Grammarly Premium® Academic, Microsoft® Editor/Copilot for language polishing of the manuscript. Additionally, EndNote is used for managing references, and Microsoft Word is used for writing.
References
- 1.
Heimsch KC, Bleicker T, Best TD, Presser LD, Molenkamp R, Jaaskelainen AJ, et al. Coordinated implementation of a conventional PCR assay to detect all Ebola and Marburg virus species in a European laboratory network. Journal of Clinical Virology. 2025; 178 :105808 - 2.
Zell BN, Swenson VA, Lu SC, Wang L, Barry MA, Ebihara H, et al. Development of a pentacistronic Ebola virus minigenome system. Viruses. 2025; 17 (5) - 3.
Ghorpade VK, Geddugol BJ. Effectiveness of a teaching program on Ebola virus knowledge among nursing students. Cureus. 2025; 17 (4):e82832 - 4.
Branda F, Ciccozzi M, Scarpa F. Epidemiology and genetic characterization of distinct Ebola Sudan outbreaks in Uganda. Infectious Disease Reports. 2025; 17 (3) - 5.
Morales-Tenorio M, Lasala F, Garcia-Rubia A, Aledavood E, Heung M, Olal C, et al. From diarylsulfides to diarylamines: New Ebola virus entry inhibitors with improved metabolic stability. Journal of Medicinal Chemistry. 2025 - 6.
Kikwango EM, Akilimali PZ, Tran NT. Impact of most promising Ebola therapies on survival: A secondary analysis during the tenth outbreak in the Democratic Republic of Congo. Virology Journal. 2025; 22 (1):144 - 7.
Rahimi R, Solimannejad M, Abnosi MH. In silico study of salicylic acid derivatives as inhibitors of Ebola proteins through molecular docking. Computational Biology and Chemistry. 2025; 119 :108504 - 8.
Sutton C, Baffour K, Soard C, Ramanujam S, Patel R, Santra S, et al. Plasmonic nanoceria: A plasmon-enhanced nanohybrid for rapid and sensitive detection of Ebola glycoprotein. ACS Applied Nano Materials. 2025; 8 (18):9604-9612 - 9.
Cenat JM, Moshirian Farahi SMM, Bukaka J, Balayulu-Makila O, Luyeye N, Derivois D, et al. Symptoms and determinants of post-traumatic stress disorder and psychological distress among adolescents in Ebola virus disease affected areas: A longitudinal design. European Child & Adolescent Psychiatry. 2025 - 10.
Hartley CD, Linderman S, Fashina T, Ward L, Drews-Botsch C, Pratt C, et al. Understanding the pathogenesis of uveitis in Ebola virus disease survivors: A study protocol for clinical, molecular virologic, and immunologic characterization. medRxiv. 2025 - 11.
Loaiza-Cano V, Pardo-Rodriguez D, Vazquez CA, Pastrana Restrepo M, Burgos JC, Avila JS, et al. Antiviral in vitro activity of a novel dichlorinated tyrosine methyl ester derivative against the infection of two flaviviruses of public health concern, dengue and Zika virus. Biochemical and Biophysical Research Communications. 2025; 775 :152057 - 12.
Almeida JV, Abdala BB, Rabelo NC, Gomes ME, Ferreira Bastos E, Llerena JC Jr, et al. Autosomal recessive primary microcephaly in sibs in time of Zika epidemic: A case report. Frontiers in Genetics. 2025; 16 :1565296 - 13.
Shi H, Feng S, Naeem A, Huang B, Tan W, Zheng L, et al. Bioprofiling and vaccine development for Zika virus. Science China. Life Sciences. 2025 - 14.
Uono Sanchez A, Saura Martins AG, Montebello Medeiros Bahe AP, Oliveira Zucchi F, Borges de Almeida MM, Vaz de Almeida MB, et al. Gross motor function and musculoskeletal deformities in children with congenital Zika virus syndrome. Journal of Musculoskeletal & Neuronal Interactions. 2025; 25 (2):172-177 - 15.
Mareto LK, Metzker SA, Maciel CG, Vilharba BLA, Venancio FA, Fernandes WS, et al. Investigating the association between yellow fever vaccination and symptomatic acute Zika virus infection: A case-control study. Revista da Sociedade Brasileira de Medicina Tropical. 2025; 58 :e004042025 - 16.
Marquis VB, de Oliveira Melo A, Pradella-Hallinan M, de Vasconcelos Ataide G, Carvalho M, de Barros Miranda-Filho D, et al. Investigation of sleep patterns and electroencephalographic characteristics in children with microcephaly associated with congenital Zika syndrome and severe cerebral palsy. Pediatric Neurology. 2025; 169 :69-73 - 17.
Ma ZH, Xing L. Neurovirulence of Zika virus-encoded proteins. Archives of Virology. 2025; 170 (7):150 - 18.
Lima F, Iriart JAB, Massad E, Kinsman J. Perceptions, knowledge and guidelines developed by health professionals in the post-epidemic context of the Zika virus. Ciência & Saúde Coletiva. 2025; 30 (suppl 1):e09892023 - 19.
Das M, Kumar V, Madhukalya R, Saroj A, Rout A, Upadhyay A, et al. Purification, refolding, and pH-dependent stability evaluation of Zika virus EDIII protein. International Microbiology. 2025 - 20.
Sant’ana JF, Tureta EF, Rosa RLD, Calegari-Alves YP, Faustino AM, Marques AL, et al. Zika virus infection in a non-neural cell host promotes differential expression of proteins associated with neurological conditions. Anais da Academia Brasileira de Ciências. 2025; 97 (suppl 2):e20240849 - 21.
Xu T, Li K, Huang S, Ivanov KI, Yang S, Ji Y, et al. Anti-SARS-CoV-2 prodrug ATV006 has broad-spectrum antiviral activity against human and animal coronaviruses. Acta Pharmaceutica Sinica B. 2025; 15 (5):2498-2510 - 22.
Barber CA, Chien LC, Labus B, Crank K, Papp K, Gerrity D, et al. Application of joinpoint regression to SARS-CoV-2 wastewater-based epidemiology in Las Vegas, Nevada, USA. Epidemiology and Infection. 2025; 153 :e68 - 23.
Debarre F, Hensel Z. A critical reexamination of recovered SARS-CoV-2 sequencing data. Molecular Biology and Evolution. 2025; 42 (6) - 24.
Bloom JD. The data are insufficient to confidently root the SARS-CoV-2 phylogenetic tree. Molecular Biology and Evolution. 2025; 42 (6) - 25.
Baba S, Hayashi H, Yoshida S, Yin N, Shimamura M, Morishita R, et al. Development of a peptide-based vaccine using a T cell epitope derived from SARS-CoV-2. iScience. 2025; 28 (6):112542 - 26.
Chan AKP, Suwanmanee S, Casadevall A, Shoham S, Bloch EM, Gebo KA, et al. The effect of early COVID-19 treatment with convalescent plasma on antibody responses to SARS-CoV-2. Microbiology Spectrum. 2025:e0300624 - 27.
Oliveira JSB, Mussi FC, Coelho ACC, Teixeira JRB, Santos TAD, Menezes AA, et al. Factors associated with SARS-COV-2 positivity in nursing workers. Revista da Escola de Enfermagem da USP. 2025; 59 :e20240301 - 28.
Foster CSP, Walker GJ, Jean T, Wong M, Brassil L, Isaacs SR, et al. Long-term serial passaging of SARS-CoV-2 reveals signatures of convergent evolution. Journal of Virology. 2025:e0036325 - 29.
Liu JK, Zhou ZS, Wang SH, Zuo SY, Lu XF, He Y, et al. SARS-CoV-2 N protein interacts with Nav1.7 to promote pathological pain. Pain. 2025 - 30.
Robertson NM, Coleman BL, Harrison R, Cooper C, Nadarajah J, Smieja M, et al. Trends in testing for SARS-CoV-2 among healthcare workers in a Canadian cohort study during the COVID-19 pandemic, June 2020 to November 2023. Canadian Journal of Infectious Diseases and Medical Microbiology. 2025; 2025 :1858884 - 31.
Barbosa AN, Chebabo A, Starling C, Perez C, Cunha CA, de Luna D, et al. Pan-American guidelines for the treatment of SARS-CoV-2/COVID-19: A joint evidence-based guideline of the Brazilian Society of Infectious Diseases (SBI) and the Pan-American Association of Infectious Diseases (API). Annals of Clinical Microbiology and Antimicrobials. 2023; 22 (1):67 - 32.
Carrion-Nessi FS, Ascanio LC, Pineda-Arape AG, Omana-Avila OD, Mendoza-Millan DL, Romero SR, et al. New daily persistent headache after SARS-CoV-2 infection in Latin America: A cross-sectional study. BMC Infectious Diseases. 2023; 23 (1):877 - 33.
Rodriguez-Morales AJ, Barbosa AN, Cimerman S. Editorial: New therapeutic approaches for SARS-CoV-2/COVID-19. Frontiers in Immunology. 2023; 14 :1276279 - 34.
Valderrama-Beltran S, Cuervo-Rojas J, Martinez-Vernaza S, Alvarez-Moreno CA, Rodriguez-Morales AJ. SARS-CoV-2 vaccination strategies: Should the extended dosing interval strategy be implemented in future pandemics? Travel Medicine and Infectious Disease. 2023; 56 :102650 - 35.
Cardona-Ospina JA, Giselle-Badillo A, Calvache-Benavides CE, Rodriguez-Morales AJ. Ebola virus disease: An emerging zoonosis with importance for travel medicine. Travel Medicine and Infectious Disease. 2014; 12 (6 Pt A):682-683 - 36.
Cruz-Calderon S, Nasner-Posso KM, Alfaro-Toloza P, Paniz-Mondolfi AE, Rodriguez-Morales AJ. A bibliometric analysis of global Ebola research. Travel Medicine and Infectious Disease. 2015; 13 (2):202-204 - 37.
Patino-Barbosa AM, Arroyave-Valencia F, Garcia-Ramirez LM, Vallejo-Atehortua E, Arciniegas-Pantoja M, Rodriguez-Morales AJ, et al. Healthcare students’ and workers’ knowledge about epidemiology and symptoms of Ebola in one city of Colombia. The Journal of Hospital Infection. 2015; 90 (4):356-358 - 38.
Rodriguez-Morales AJ, Castaneda-Hernandez DM, McGregor A. What makes people talk about Ebola on social media? A retrospective analysis of Twitter use. Travel Medicine and Infectious Disease. 2015; 13 (1):100-101 - 39.
Rodriguez-Morales AJ, Henao DE, Franco TB, Mayta-Tristan P, Alfaro-Toloza P, Paniz-Mondolfi AE. Ebola: A latent threat to Latin America. Are we ready? Travel Medicine and Infectious Disease. 2014; 12 (6 Pt A):688-689 - 40.
Rodriguez-Morales AJ, Marin-Rincon HA, Sepulveda-Arias JC, Paniz-Mondolfi AE. Assessing the potential migration of people from Ebola affected west African countries to Latin America. Travel Medicine and Infectious Disease. 2015; 13 (3):264-266 - 41.
Sah R, Mohanty A, Mehta V, Satapathy P, Padhi BK, Rodriguez-Morales AJ. The Ebola resurgence in Democratic Republic of Congo. Annals of Medicine and Surgery. 2022; 82 :104616 - 42.
Cardona-Cardona AF, Rodriguez Morales AJ. Severe abdominal pain in a patient with Zika infection: A case in Risaralda, Colombia. Journal of Infection and Public Health. 2016; 9 (3):372-373 - 43.
Rodriguez-Morales AJ, Patino-Cadavid LJ, Lozada-Riascos CO, Villamil-Gomez WE. Mapping Zika in municipalities of one coastal department of Colombia (Sucre) using geographic information systems during the 2015-2016 outbreak: Implications for public health and travel advice. International Journal of Infectious Diseases. 2016; 48 :70-72 - 44.
Villamil-Gomez WE, Gonzalez-Camargo O, Rodriguez-Ayubi J, Zapata-Serpa D, Rodriguez-Morales AJ. Dengue, chikungunya and Zika co-infection in a patient from Colombia. Journal of Infection and Public Health. 2016; 9 (5):684-686 - 45.
Villamil-Gomez WE, Rodriguez-Morales AJ. Reply: Dengue RT-PCR-positive, chikungunya IgM-positive and Zika RT-PCR-positive co-infection in a patient from Colombia. Journal of Infection and Public Health. 2017; 10 (1):133-134 - 46.
Villamil-Gomez WE, Rodriguez-Morales AJ, Uribe-Garcia AM, Gonzalez-Arismendy E, Castellanos JE, Calvo EP, et al. Zika, dengue, and chikungunya co-infection in a pregnant woman from Colombia. International Journal of Infectious Diseases. 2016; 51 :135-138 - 47.
Chemaitelly H, Ayoub HH, Coyle P, Tang P, Hasan MR, Yassine HM, et al. Assessing healthy vaccinee effect in COVID-19 vaccine effectiveness studies: A national cohort study in Qatar. eLife. 2025; 14 - 48.
Kim J, Hoskinson C, Nichols E, Illapperuma-Wood C, Fischer A, Ben-Umeh K, et al. COVID-19 and risk of self-harm, suicidal ideation, and poisoning in children and adolescents. Annals of Medicine. 2025; 57 (1):2516698 - 49.
Mrotzek P, Hofmann SC, Kreuter A, Appelbaum S, Wesselmann U, Wehry UP, et al. Cutaneous squamous cell carcinoma in the post-COVID-19 era: Dramatic increase of new cases in 2023 in two German skin tumour centers. Acta Dermato-Venereologica. 2025; 105 :adv43609 - 50.
Crump J, Jackson D, Algoso M, Peters K. Deployment of perioperative nurses from their clinical specialty during the COVID-19 pandemic: An integrative review. Journal of Advanced Nursing. 2025 - 51.
Li P, Chen Y, Cao X, Wang Z, Sai L, Wang L. Diagnosis of invasive pulmonary aspergillosis using metagenomic next-generation sequencing and conventional microbial tests post-COVID-19 pandemic. Microbiology Spectrum. 2025:e0012125 - 52.
Bogg T, Milad E, Godfrey O. A disposition-belief-motivation framework for COVID-19 boosters: Prospective tests in a U.S. sample. Health Psychology. 2025 - 53.
Balevic SJ, Gonzalez D, Smith PB, Powderly WG, Schmid A, Kang A, et al. Infliximab pharmacokinetics, dosing, and response in hospitalized patients with COVID-19 pneumonia: A secondary analysis of a multinational randomized clinical trial (ACTIV-1 IM). Journal of Clinical Pharmacology. 2025 - 54.
Steffen Johansson R, Loewenstein D, Lodin K, Bruchfeld J, Runold M, Stahlberg M, et al. Long-term coronary microvascular and cardiac dysfunction after severe COVID-19 hospitalization. JAMA Network Open. 2025; 8 (6):e2514411 - 55.
Lin T, Wang Y, Thier K, Nan X. Normative influence in a time of distrust and polarization: How perceived social norms predict COVID-19 vaccination intentions among black Americans. Journal of Behavioral Medicine. 2025 - 56.
Agyei-Manu E, Atkins N, Nundy M, St-Jean C, Gornall-Wick A, Birley E, et al. Characteristics of influenza, SARS-CoV-2, and RSV surveillance systems that utilise ICD-coded data: A systematic review. Journal of Global Health. 2025; 15 :04177 - 57.
Kim Y, Fournie G, Tizzani P, Torres G, Metras R, Pfeiffer D, et al. Evaluation of global outbreak surveillance performance for high pathogenicity avian influenza and African swine fever. Nature Communications. 2025; 16 (1):4737 - 58.
Berkessa T, Tayachew A, Gebeyehu A, Teka G, Shure W, Agune A, et al. Evaluation of the sentinel surveillance system for influenza-like illness and severe acute respiratory infection in Ethiopia during the COVID-19 pandemic, 2021-2023. BMC Health Services Research. 2025; 25 (1):759 - 59.
Dharmayanti N, Nurjanah D, Indriani R, Suyatno T, Nuradji H. Genomic surveillance of influenza a virus in live bird markets during the COVID-19 pandemic. Veterinary World. 2025; 18 (4):955-968 - 60.
Goodfellow SM, Bard JD, Costales C. Implications of subtyping influenza A amongst H5N1 surveillance efforts. Journal of Clinical Virology. 2025; 179 :105810 - 61.
Kwaah B, DeMarcus LS, Thervil JW, Jenkins WN, Gruner WE, Hartless TR, et al. Mid-season vaccine effectiveness estimates for influenza: The department of defense global respiratory pathogen surveillance program, 2024-2025 season. MSMR. 2025; 32 (5):42-43 - 62.
Khan T, Halder S, Das RS, Jaiswal A, Leo PHS, Mahato A, et al. Molecular epidemiology of influenza, respiratory syncytial virus, SARS-CoV-2, other respiratory viruses and bacteria among children 0-2-year-olds in West Bengal: A one-year influenza-like illness surveillance study (2022-2023). Frontiers in Epidemiology. 2025; 5 :1578951 - 63.
Wannigama DL, Amarasiri M, Phattharapornjaroen P, Hurst C, Modchang C, Besa JJV, et al. Surveillance of avian influenza through bird guano in remote regions of the global south to uncover transmission dynamics. Nature Communications. 2025; 16 (1):4900 - 64.
van der Vries E, Germeraad EA, Kroneman A, Dieste-Perez L, Eggink D, Willems E, et al. Swine influenza virus surveillance programme pilot to assess the risk for animal and public health, the Netherlands, 2022 to 2023. Euro Surveillance. 2025; 30 (22) - 65.
Rapi MC, Martin AMM, Lelli D, Lavazza A, Raimondi S, Farioli M, et al. Virological passive surveillance of avian influenza and arboviruses in wild birds: A two-year study (2023-2024) in Lombardy, Italy. Microorganisms. 2025; 13 (5) - 66.
Ou G, Tang Y, Liu J, Hao Y, Chen Z, Huang T, et al. Automated robot and artificial intelligence-powered wastewater surveillance for proactive mpox outbreak prediction. Biosafety and Health. 2024; 6 (4):225-234 - 67.
Malembi E, Escrig-Sarreta R, Ntumba J, Beiras CG, Shongo R, Bengehya J, et al. Clinical presentation and epidemiological assessment of confirmed human mpox cases in DR Congo: A surveillance-based observational study. Lancet. 2025; 405 (10490):1666-1675 - 68.
Reyes Nieva H, Zucker J, Tucker E, McLean J, DeLaurentis C, Gunaratne S, et al. Development of machine learning-based mpox surveillance models in a learning health system. Sexually Transmitted Infections. 2025 - 69.
Tiwari A, Kalonji T, Miller T, Van Den Bossche T, Krolicka A, Muhindo-Mavoko H, et al. Emergence and global spread of Mpox clade Ib: Challenges and the role of wastewater and environmental surveillance. The Journal of Infectious Diseases. 2025; 231 (5):e825-e8e9 - 70.
Vakaniaki EH, Merritt S, Linsuke S, Malembi E, Muyembe F, Lunyanga L, et al. Establishment of a regional Mpox surveillance network in central Africa: Shared experiences in an endemic region. Global Health Research and Policy. 2025; 10 (1):14 - 71.
Wannigama DL, Amarasiri M, Phattharapornjaroen P, Hurst C, Modchang C, Wang Y, et al. Global participatory wastewater surveillance to understand Mpox clade diversity in war and conflict-affected countries. Journal of Travel Medicine. 2025 - 72.
Ntoumi F, Strub-Wourgaft N. Integrating research into surveillance: Enhancing the response to mpox. Lancet. 2025; 405 (10490):1642-1643 - 73.
Duffy J, Yih WK, Walton K, DeSilva MB, Glanz JM, Hambidge SJ, et al. JYNNEOS vaccine safety surveillance in the vaccine safety datalink during the 2022 Mpox outbreak in the United States. Infection. 2024 - 74.
MacGibbon J, Storer D, Bavinton BR, Cornelisse VJ, Broady TR, Chan C, et al. Mpox vaccination coverage among Australian gay and bisexual men and non-binary people: Results of behavioural surveillance in early 2024. Vaccine. 2025; 55 :127014 - 75.
Amisi Kengea L, Ihekambangu Ngwakaha B, Masamba Bikoki W, Ndumbi Temuangudi V, Nsinga Bungiena JC, Kape Kalume JJ, et al. Profile of Mpox cases identified during surveillance of the Kokolo health zone in Kinshasa (DRC) from August to November 2024. Médecine Tropicale et Santé Internationale (MTSI). 2025; 5 (1) - 76.
Yambayamba MK, Ruegg S. Setting-based surveillance and one health in the Mpox response. One Health Outlook. 2025; 7 (1):24 - 77.
Bangwen E, Diavita R, De Vos E, Vakaniaki EH, Nundu SS, Mutombo A, et al. Suspected and confirmed Mpox cases in DR Congo: A retrospective analysis of national epidemiological and laboratory surveillance data, 2010-23. Lancet. 2025; 405 (10476):408-419 - 78.
Abdelaal A, Reda A, Hassan AR, Mashaal A, Abu Serhan H, Katamesh BE, et al. Monkeypox-associated manifestations and complications involving the eye: A systematic review and meta-analysis of previous and current outbreaks. Asia-Pacific Journal of Ophthalmology (Philadelphia, Pa.). 2023; 12 (3):326-337 - 79.
Cimerman S, Chebabo A, Cunha CAD, Barbosa AN, Rodriguez-Morales AJ. Human monkeypox preparedness in Latin America - Are we ready for the next viral zoonotic disease outbreak after COVID-19? The Brazilian Journal of Infectious Diseases. 2022; 26 (3):102372 - 80.
Pecho-Silva S, Navarro-Solsol AC, Panduro-Correa V, Rabaan AA, Maguina JL, Rodriguez-Morales AJ, et al. Viral replication and antibody kinetics in the recognition of asymptomatic COVID-19 patients. Chemotherapy. 2021; 66 (3):53-57 - 81.
Srivastava S, Sharma D, Kumar S, Sharma A, Rijal R, Asija A, et al. Emergence of Marburg virus: A global perspective on fatal outbreaks and clinical challenges. Frontiers in Microbiology. 2023; 14 :1239079 - 82.
Acosta-Espana JD, Romero-Alvarez D, Luna C, Rodriguez-Morales AJ. Infectious disease outbreaks in the wake of natural flood disasters: Global patterns and local implications. Le Infezioni in Medicina. 2024; 32 (4):451-462 - 83.
Sah R, Srivastava S, Kumar S, Koteswara Rao GSN, Mehta R, Mohanty A, et al. Ongoing hMPV outbreaks in China and other Asian countries. Le Infezioni in Medicina. 2025; 33 (1):1-3 - 84.
Bonilla-Aldana DK, Rivera-Casas E, Moreno-Ramos E, Barboza JJ, Salas-Matta LA, Rodriguez-Morales AJ. Mapping bovine brucellosis in Colombia with geographical information systems, 2009-2019 - Implications for Onehealth. New Microbes New Infections. 2024; 56 :101197 - 85.
Bonilla-Aldana DK, Ruiz-Saenz J, Martinez-Gutierrez M, Villamil-Gomez W, Mantilla-Meluk H, Arrieta G, et al. Zero by 2030 and Onehealth: The multidisciplinary challenges of rabies control and elimination. Travel Medicine and Infectious Disease. 2023; 51 :102509 - 86.
Musso D, Rodriguez-Morales AJ, Levi JE, Cao-Lormeau VM, Gubler DJ. Unexpected outbreaks of arbovirus infections: Lessons learned from the Pacific and tropical America. The Lancet Infectious Diseases. 2018; 18 (11):e355-ee61 - 87.
Reda A, Sah R, Rodriguez-Morales AJ, Shah J. Viral replication and infectivity of monkeypox through semen. The Lancet Infectious Diseases. 2022; 22 (11):1531-1532 - 88.
Rodriguez-Morales AJ, Drexler JF. Re-emergence of Oropouche virus in Brazil and Latin America. The Lancet Infectious Diseases. 2025; 25 (2):137-139 - 89.
Srivastava S, Dhoundiyal S, Kumar S, Kaur A, Khatib MN, Gaidhane S, et al. Yellow fever: Global impact, epidemiology, pathogenesis, and integrated prevention approaches. Le Infezioni in Medicina. 2024; 32 (4):434-450 - 90.
Friedman SR, Jordan AE, Perlman DC, Nikolopoulos GK, Mateu-Gelabert P. Emerging zoonotic infections, social processes and their measurement and enhanced surveillance to improve zoonotic epidemic responses: A “big events” perspective. International Journal of Environmental Research and Public Health. 2022; 19 (2) - 91.
Martz M, Akhverdyan N, Wilson MP, Walker J, Gorvetzian S, Chauhan L, et al. Adherence to bone mineral density screening recommendations in older adults with HIV. AIDS Research and Human Retroviruses. 2025 - 92.
Mbhele N, Chimukangara B, Tyers L, Maldarelli F, Redd AD. Advancements in single-cell techniques for examining the HIV reservoir: Pathways to a cure. MBio. 2025:e0065525 - 93.
Yang C, Wang R, Cheng C, Yu J, Lu K, Li H, et al. Amyloid-like fibrils derived from beta-sheets of gp120 contribute to the neuronal pathology of HIV-associated neurocognitive disorders. Acta Pharmaceutica Sinica B. 2025; 15 (4):2273-2277 - 94.
Watera C, Da Silva JF, Namayanja G, Asio JN, Ssemwanga D, Pals S, et al. HIV-1 drug resistance among people living with HIV receiving dolutegravir-based anti-retroviral regimens in Uganda: A national laboratory-based survey using remnant viral load samples, 2022. The Journal of Antimicrobial Chemotherapy. 2025 - 95.
Rambiki E, Thawani A, Kapenga D, Malunda C, Mseke B, Mpesi P, et al. Inability-to-walk-unaided-a single WHO danger sign predicts in-hospital mortality in people with HIV under routine care conditions in a low-resource setting. Therapeutic Advances in Infectious Disease. 2025; 12 :20499361251341385 - 96.
Mutalange M, Siame L, Cheelo C, Masenga SK, Hamooya BM. Kidney impairment in HIV: An insight into the burden and associated factors among adults on antiretroviral therapy in Zambia. A retrospective cross-sectional study. Therapeutic Advances in Infectious Disease. 2025; 12 :20499361251340795 - 97.
Yan A, Kundu S, Samuels DC, Bailin S, Xu K, So-Armah K, et al. Mitochondrial DNA haplogroups, biomarkers of inflammation and immune activation, and risk of diabetes in veterans with and without HIV. The Journal of Infectious Diseases. 2025 - 98.
Duggal M, Sarna A, Dahiya N, Singh RJ, Jeon S, Subramanian A, et al. A pilot study to evaluate the feasibility and acceptability of a mobile phone counselling intervention for perinatal women living with HIV and depression in India. Oxford Open Digital Health. 2025; 3 :oqaf012 - 99.
Acharya S, Karanjkar V, Goyal M, Deshpande PV, Anonymous, Setia MS, et al. Prevalence of hypertension and its associated factors among adult people living with HIV/AIDS at anti-retroviral treatment (ART) centers in Mumbai, India. HIV AIDS (Auckland-NZ). 2025; 17 :105-119 - 100.
Yang H, Jin X, Chen H, Dong L, Dai J, Yang M, et al. Tracking HIV-1 genetic epidemiological characteristics among recent infections in Yunnan, China. AIDS Research and Human Retroviruses. 2025 - 101.
Nishiura H, Ito K, Anzai A, Kobayashi T, Piantham C, Rodríguez-Morales AJ. Relative reproduction number of SARS-CoV-2 omicron (B.1.1.529) compared with delta variant in South Africa. Journal of Clinical Medicine. 2021; 11 (1) - 102.
Tilak R, Ray S, Tilak VW, Mukherji S. Dengue, chikungunya … and the missing entity - Zika fever: A new emerging threat. Medical Journal, Armed Forces India. 2016; 72 (2):157-163 - 103.
Nishiura H, Mizumoto K, Villamil-Gómez WE, Rodríguez-Morales AJ. Preliminary estimation of the basic reproduction number of Zika virus infection during Colombia epidemic, 2015-2016. Travel Medicine and Infectious Disease. 2016; 14 (3):274-276 - 104.
Reperant LA, Osterhaus A. AIDS, Avian flu, SARS, MERS, Ebola, Zika… what next? Vaccine. 2017; 35 (35 Pt A):4470-4474 - 105.
Hu VT, Ezzatpour S, Selivanovitch E, Sahler J, Pal S, Carter J, et al. Cell-free expression of Nipah virus transmembrane proteins for proteoliposome vaccine design. ACS Nano. 2025 - 106.
Sharma S, Yadav PD, Cherian S. Comprehensive immunoinformatics and bioinformatics strategies for designing a multi-epitope based vaccine targeting structural proteins of Nipah virus. Frontiers in Immunology. 2025; 16 :1535322 - 107.
Wang F, Chen R, Zhong J, Zhou A, Peng R, Xue B, et al. Construction of minigenome replicon of Nipah virus and investigation of biological activity. Viruses. 2025; 17 (5) - 108.
Jayachandran RB, Renner M. From disorder to order: Cryo-EM reveals RNA-dependent remodeling of Nipah virus polymerase. Trends in Biochemical Sciences. 2025 - 109.
Shabbir MA, Amin A, Hasnain A, Shakeel A, Gul A. Immunoinformatics-driven design of a multi-epitope vaccine against Nipah virus: A promising approach for global health protection. Journal, Genetic Engineering & Biotechnology. 2025; 23 (2):100482 - 110.
Chen S, Zhang X, Yao Y, Chuai X, Li K, Zhang B, et al. An intein-spliced Nipah G protein ferritin nanoparticle vaccine provides complete protection against lethal Nipah virus challenge. ACS Nano. 2025 - 111.
Sun YQ, Hay SI, Fang LQ, Liu W. Nipah spillover risk and large-scale spatial modelling studies - Authors’ reply. The Lancet Planetary Health. 2025; 9 (5):e354-e3e5 - 112.
Sharma D. Nipah virus in India. Indian Journal of Medical Microbiology. 2025; 56 :100884 - 113.
Yadav PD, Baid K, Patil DY, Shirin T, Rahman MZ, Peel AJ, et al. A one health approach to understanding and managing Nipah virus outbreaks. Nature Microbiology. 2025; 10 (6):1272-1281 - 114.
Pandey P, Chauhan P, Pandey S, Lakhanpal S, Padmapriya G, Mishra S, et al. An updated review on Nipah virus infection with a focus on encephalitis, vasculitis, and therapeutic approaches. Current Topics in Medicinal Chemistry. 2025 - 115.
Oeschger TM, McCloskey DS, Buchmann RM, Choubal AM, Boza JM, Mehta S, et al. Early warning diagnostics for emerging infectious diseases in developing into late-stage pandemics. Accounts of Chemical Research. 2021; 54 (19):3656-3666 - 116.
da Silva PG, Mesquita JR, de São José Nascimento M, VAM F. Viral, host and environmental factors that favor anthropozoonotic spillover of coronaviruses: An opinionated review, focusing on SARS-CoV, MERS-CoV and SARS-CoV-2. Science of the Total Environment. 2021; 750 :141483 - 117.
Alhamlan FS, Al-Qahtani AA. SARS-CoV-2 variants: Genetic insights, epidemiological tracking, and implications for vaccine strategies. International Journal of Molecular Sciences. 2025; 26 (3) - 118.
Cancela F, Ramos N, Smyth DS, Etchebehere C, Berois M, Rodríguez J, et al. Wastewater surveillance of SARS-CoV-2 genomic populations on a country-wide scale through targeted sequencing. PLoS One. 2023; 18 (4):e0284483 - 119.
Beltran RM, Holloway IW, Hong C, Miyashita A, Cordero L, Wu E, et al. Social determinants of disease: HIV and COVID-19 experiences. Current HIV/AIDS Reports. 2022; 19 (1):101-112 - 120.
Thompson GR 3rd, Desai AN. Addressing antifungal drug resistance - A “one health-one world” challenge. The New England Journal of Medicine. 2025 - 121.
Fuller D, Andresen-Bundus H, Pagonas N, Jaehn P, Ukena C, Godde K, et al. Adverse socioeconomic factors are associated with a widening gap in one-year health-related quality of life after acute myocardial infarction. Scientific Reports. 2025; 15 (1):19791 - 122.
Ci Z. Blue Hg dilemma and implications for nature-based solution and one health approach. Eco-Environment & Health. 2025; 4 (2):100152 - 123.
Fujihara M, Comizzoli P. Human and wildlife biobanks of germplasms and reproductive tissues can contribute to a broader concept of one health. F&S Reports. 2025; 6 (Suppl 1):63-66 - 124.
Moussa LG, Sonmez OF, Bedi R. Incorporating oral health into the one health agenda: Contributions and implications. Science in One Health. 2025; 4 :100111 - 125.
Ottinger MA, Geiselman C. One health and the exposome: Providing insights for wildlife health and reproduction. F&S Reports. 2025; 6 (Suppl 1):55-62 - 126.
Capps B. A one health economy. Global Bioethics. 2025; 36 (1):2511516 - 127.
Chung PY. One health strategies in combating antimicrobial resistance: A southeast Asian perspective. Journal of Global Health. 2025; 15 :03025 - 128.
Gravelsins LL, Galea LAM. One size does not fit all: How type of menopause and hormone therapy matters for brain health. The British Journal of Psychiatry. 2025:1-14 - 129.
Chung YS, Sohn EJ, Cho H, Jang B, Lee M, Yang SJ, et al. Prevalence and antimicrobial resistance of Acinetobacter baumannii in the livestock industry in South Korea under a one health perspective. One Health. 2025; 20 :101071 - 130.
Mohapatra RK, Sahu AR, Mishra S, Tiady SK, Tuglo LS. Tanzania confirms its second MVD outbreak: A constantly emerging outbreak calls for effective countermeasures in light of one health approach and preparedness to counter future epidemics. One Health. 2025; 20 :101070 - 131.
Fonzo GA, Doss MK, Nemeroff CB. There’s more than one way to bring health back: Divergent effects of psilocybin and escitalopram treatment on emotional brain function in depression. The American Journal of Psychiatry. 2025; 182 (6):512-515 - 132.
Bartlett ML, Uhart M. Leveraging one health as a sentinel approach for pandemic resilience. Virology Journal. 2024; 21 (1):269 - 133.
Alissa M, Alsuwat MA, Alzahrani KJ. Neurological manifestations of Flaviviridae, Togaviridae, and Peribunyaviridae as vector-borne viruses. Reviews in Medical Virology. 2024; 34 (4):e2571 - 134.
Lee JH, Agarwal A, Mahendradas P, Lee CS, Gupta V, Pavesio CE, et al. Viral posterior uveitis. Survey of Ophthalmology. 2017; 62 (4):404-445 - 135.
Garout MA, Saleh SAK, Adly HM, Abdulkhaliq AA, Khafagy AA, Abdeltawab MR, et al. Post-COVID-19 syndrome: Assessment of short- and long-term post-recovery symptoms in recovered cases in Saudi Arabia. Infection. 2022; 50 (6):1431-1439 - 136.
Low ZXB, Yong SJ, Alrasheed HA, Al-Subaie MF, Al Kaabi NA, Alfaresi M, et al. Serotonergic psychedelics as potential therapeutics for post-COVID-19 syndrome (or long COVID): A comprehensive review. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 2025; 137 :111279 - 137.
Rodriguez-Morales AJ, Lopez-Echeverri MC, Perez-Raga MF, Quintero-Romero V, Valencia-Gallego V, Galindo-Herrera N, et al. The global challenges of the long COVID-19 in adults and children. Travel Medicine and Infectious Disease. 2023; 54 :102606 - 138.
Ewing AG, Joffe D, Blitshteyn S, Brooks AES, Wist J, Bar-Yam Y, et al. Long COVID clinical evaluation, research and impact on society: A global expert consensus. Annals of Clinical Microbiology and Antimicrobials. 2025; 24 (1):27 - 139.
van de Veerdonk FL. COVID-19 pneumonia and cytokine storm syndrome. Advances in Experimental Medicine and Biology. 2024; 1448 :307-319 - 140.
Baala L, Benzekri-Lefevre D, Bret L, Guillaume C, Courtellemont L, El Khalil A, et al. Case report: Co-infection with SARS-CoV-2 and influenza H1N1 in a patient with acute respiratory distress syndrome and a pulmonary sarcoidosis. F1000Research. 2020; 9 :1482 - 141.
Baumann J, Knüpfer M, Ouedraogo J, Traoré BY, Heitzer A, Kané B, et al. Lassa and Crimean-Congo hemorrhagic fever viruses, Mali. Emerging Infectious Diseases. 2019; 25 (5):999-1002 - 142.
O’Hearn AE, Voorhees MA, Fetterer DP, Wauquier N, Coomber MR, Bangura J, et al. Serosurveillance of viral pathogens circulating in west Africa. Virology Journal. 2016; 13 (1):163 - 143.
Angerami RN, Socorro Souza Chaves TD, Rodriguez-Morales AJ. Yellow fever outbreaks in south America: Current epidemiology, legacies of the recent past and perspectives for the near future. New Microbes New Infections. 2025; 65 :101580 - 144.
Poran I, Basharim B, Leibovici-Weisman Y, Michaelis M, Ghantous N, Eliakim-Raz N. Characteristics and clinical outcomes of the West Nile virus outbreak in Israel 2024: A retrospective cohort study. Diagnostic Microbiology and Infectious Disease. 2025; 113 (2):116936 - 145.
Katzenellenbogen G, Canetti M, Margalit I, Shusterman Y, Simchovitz-Gesher A, Naveh L, et al. Correction: West Nile virus outbreak in Israel 2024 compared with previous seasons: A retrospective study. Infectious Disease and Therapy. 2025 - 146.
Freick M, Vogt I, Schroter S, Kohl R, Heidl D, Schreiter R, et al. Investigations on the occurrence of West Nile virus, Usutu virus and Sindbis virus RNA in avian louse flies (Diptera: Hippoboscidae) collected in Germany (2016-2022). Parasites & Vectors. 2025; 18 (1):200 - 147.
Alghamdi A, Alissa M, Alshehri MA. Mechanisms of immune evasion of West Nile virus. Reviews in Medical Virology. 2025; 35 (3):e70042 - 148.
Helal ZH, Soriano NF, Chung DH, Lee DH, Tocco N, Gazeyoglu F, et al. Molecular epidemiology of West Nile virus in raptors, Connecticut, USA, 2022: A case series with whole genome sequencing and phylogenetic analysis. Infection, Genetics and Evolution. 2025; 132 :105769 - 149.
Alatawna H, Abu-Shakra M, Schlaeffer-Yosef T, Sagy I. Neuropsychiatric lupus or West Nile encephalitis? Diagnostic dilemmas in two SLE patients and literature review. Internal and Emergency Medicine. 2025 - 150.
Abbasi E, Moemenbellah-Fard MD. Prevalence of chikungunya, dengue, and West Nile arboviruses in Iran based on enzyme-linked immunosorbent assay (ELISA): A systematic review and meta-analysis. Global Epidemiology. 2025; 9 :100202 - 151.
Komakech H, Atuyambe L, El-Jardali F, Orach CG. Understanding the organization and delivery of health services following the repatriation of south Sudanese refugees from the West Nile districts in Uganda. Conflict and Health. 2025; 19 (1):32 - 152.
Kuhn KG, Shelton K, Sanchez G, Zamor R, Bohanan K, Nichols M, et al. Wastewater surveillance as a tool for understanding West Nile virus transmission and distribution in Oklahoma. Science of the Total Environment. 2025; 983 :179707 - 153.
Kocabiyik DZ, Alvarez LF, Durigon EL, Wrenger C. West Nile virus - A re-emerging global threat: Recent advances in vaccines and drug discovery. Frontiers in Cellular and Infection Microbiology. 2025; 15 :1568031 - 154.
Ren Q, Chen N, Mu D, Zhu MT, Shi QN, Zhou SJ, et al. Characteristics, post-exposure prophylaxis usage, and clinical features of Chinese human rabies cases, 2016-2020. PLoS Neglected Tropical Diseases. 2025; 19 (6):e0013089 - 155.
Niu J, Zhao Z, Zhang T, Liu Q, Huang L, Li S, et al. Development of an oral gut-targeted rabies virus-like particles (RVLPs) vaccine with mucosal immune adjuvant LTB via delivering of localized-release microparticles. Emerging Microbes & Infections. 2025:2515406 - 156.
Acharya KP, Phuyal S, Saied AA, Hong S, Yon DK. Don’t let war and conflict impede rabies control in Iraq. Infectious Diseases. 2025:1-2 - 157.
Liu X, Li J, Zha Y, Wang Z, Jiang Y, Zhang X, et al. The efficacy and safety of SYN023 (Zamerovimab and Mazorelvimab injection), the recombinant humanized anti-rabies virus monoclonal antibody mixture, combined with rabies vaccine in a WHO category III rabies post-exposure population: A randomized, double-blind, positive control, phase III clinical trial. Vaccine. 2025; 61 :127289 - 158.
Li J, Yang Y, Jia K, Zhang Z, Zhai X, Cao Y, et al. Exposed nucleoprotein inside rabies virus particle as an ideal target for real-time quantitative evaluation of rabies virus particle integrity in vaccine quality control. PLoS Neglected Tropical Diseases. 2025; 19 (5):e0013077 - 159.
Boutelle C, Mollentze N, Gigante C, Rocha F, Vigilato MAN, Streicker DG, et al. A logistic regression model to predict the next rabies virus host-shift event. Scientific Reports. 2025; 15 (1):19306 - 160.
Mardani R, Bahmanje A, Kazeroni YC, Khoshroo F, Roshanaie B, Sadeghche T, et al. Oxidized Mannan: A novel adjuvant candidate for enhancing immune responses in veterinary rabies vaccine. Chonnam Medical Journal. 2025; 61 (2):84-89 - 161.
Rupprecht CE, Jackson AC. A pictorial human case of “furious rabies”. Emerging Infectious Diseases. 2025; 31 (6):1270 - 162.
Kerdput V, Yodkamol V, Sookprasong M, Wongwadhunyoo W, Khunsri I, Masrinoul P, et al. Production and evaluation of rabies immunoglobulin extracted from chicken egg yolk. Biotechnology Reports (Amsterdam, Netherlands). 2025; 46 :e00897 - 163.
Kushwaha A, Mehta R, Srivastava S, Mohanty A, Sharma S, Sah S, et al. The revolving outbreaks of Japanese encephalitis in Nepal. Current Tropical Medicine Reports. 2025; 12 (1):8 - 164.
Rodriguez-Morales AJ, Cardona-Ospina JA, Fernanda Urbano-Garzon S, Sebastian Hurtado-Zapata J. Prevalence of post-chikungunya infection chronic inflammatory arthritis: A systematic review and meta-analysis. Arthritis Care & Research (Hoboken). 2016; 68 (12):1849-1858 - 165.
Cardona-Ospina JA, Rodriguez-Morales AJ, Teixeira MG, Gerardin P. Need for accurate and consistent definition of chronic chikungunya arthritis: Comment on the article by Chang et al. Arthritis & Rhematology. 2018; 70 (11):1891 - 166.
Gerardin P, Cardona-Ospina JA, Rodriguez-Morales AJ. Autoimmunity or lineage-specific virulence as drivers of chikungunya chronic arthritis: Comment on the article by Chang et al. Arthritis & Rhematology. 2018; 70 (11):1892-1893 - 167.
Rodriguez-Morales AJ, Gil-Restrepo AF, Ramirez-Jaramillo V, Montoya-Arias CP, Acevedo-Mendoza WF, Bedoya-Arias JE, et al. Post-chikungunya chronic inflammatory rheumatism: Results from a retrospective follow-up study of 283 adult and child cases in La Virginia, Risaralda, Colombia. F1000Research. 2016; 5 :360 - 168.
Fraga A, Mósca AF, Moita D, Simas JP, Nunes-Cabaço H, Prudêncio M. SARS-CoV-2 decreases malaria severity in co-infected rodent models. Frontiers in Cellular and Infection Microbiology. 2023; 13 :1307553 - 169.
Modi AR, Koval CE, Taege AJ, Modaresi Esfeh J, Eghtesad B, Narayanan Menon KV, et al. Coronavirus disease 2019 in an orthotopic liver transplant recipient living with human immunodeficiency virus. Transplant Infectious Disease. 2020; 22 (5):e13351 - 170.
Obrenovich ME, Tayahi MB, Heidt CL, Emancipator SN. Prophylaxis and remediation for future pandemic pathogens-(lessons from a post-COVID world). Microorganisms. 2022; 10 (12) - 171.
Zeng H, Du H, Shua Q, Fang J. A review regarding the article ‘the potential relationship between cardiovascular diseases and monkeypox’. Current Problems in Cardiology. 2024; 49 (8):102649 - 172.
Farahat RA, Benmelouka AY, Manirambona E, El-Sakka AA, Al-Ahdal T, Albakri K, et al. Protection against the recent monkeypox outbreaks: What options do we have? Correspondence. International Journal of Surgery. 2023 - 173.
Zumla A, Sahu S, Yeboah-Manu D, Goletti D, Nyasulu PS, Mfinanga S, et al. Breaking dependency: Strengthening the global tuberculosis response in the face of USAID cuts. Lancet. 2025; 405 (10483):958-961